ClinicalTrials.gg
Active, not recruitingNCT06097728eVOLVE-MesoUpdated Oct 23, 2026

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

A Phase 3 interventional study of Volrustomig and Pemetrexed in Unresectable Pleural Mesothelioma, sponsored by AstraZeneca. Active, not recruiting at 151 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
863
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Mesothelioma with a site in China — 8 open to participants now, 10 under way, 1 of them phase 3. Mesothelioma · China.

Enrollment
2nd of 14
863 · median 49
Started
2023
the only one that year
Phase 3
2 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
1 of 14
AstraZeneca

Among the 14 studies in Mesothelioma with a site in China, this one is the 2nd largest by enrollment, is the only one that started in 2023, is one of 2 in phase 3, and was the 7th registered.

Mesothelioma

305 studies on the registry are indexed under Mesothelioma; 60 are open to participants now.

Browse Mesothelioma studies →

Open to participants now

8 of the 14 studies in Mesothelioma with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Mesothelioma studies recruiting now, 32 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Mesothelioma with a site in China, or all of them as a file.
02

Study summary

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Read the detailed description

Adult patients with histologically proven diagnosis of pleural mesothelioma with advanced unresectable disease are eligible to be enrolled. Patients will be randomized 1:1 to receive Volrustomig (MEDI5752) + Carboplatin + Pemetrexed or the investigator's choice of platinum+Pemetrexed or Nivolumab+Ipilimumab, based on their histology.

03

Conditions studied

  • Unresectable Pleural Mesothelioma

Keywords

  • Mesothelioma
  • Pleural Mesothelioma
  • Unresectable Pleural Mesothelioma
  • Advanced pleural mesothelioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant must be ≥ 18 years at the time of screening
  • proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)
  • Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy)
  • performance status of 0 or 1 with no deterioration (that is, ECOG PS>1) over the previous 2 weeks prior to day of first dosing
  • Has per modified RECIST1.1
  • Has adequate bone marrow reserve and organ function at baseline

Key Exclusion Criteria:

  • As judged by the investigator, any condition that would interfere with evaluation of the product or interpretation of participant safety or study results.
  • Active or prior documented or inflammatory disorders
  • History of another primary with exceptions.
  • Uncontrolled intercurrent illness
  • Tuberculosis, (HBV) or (HCV), (HIV) infection that is not well controlled
  • Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment
  • Untreated or progressive CNS disease
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
863 participants (actual)

Study arms

  • Experimental
    Volrustomig + Carboplatin + pemetrexed

    Volrustomig in combination with carboplatin plus pemetrexed

    Drug: Volrustomig · Drug: Pemetrexed · Drug: Carboplatin

  • Active comparator
    Investigator's choice of standard care

    The investigator's choice of nivolumab plus ipilimumab or platinum plus pemetrexed chemotherapy for participants with epithelioid histology, and nivolumab plus ipilumab for participants with non-epithelioid histology.

    Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin · Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • MEDI5752: Administered as IV infusion

    Also known as: MEDI5752

  • Alimta: Administered as IV infusion

    Also known as: Alimta

  • Paraplatin: Administered as IV infusion

    Also known as: Paraplatin

  • Platinol: Administered as IV infusion

    Also known as: Platinol

  • Opdivo: Administered as IV infusion

    Also known as: Opdivo

  • Yervoy: Administered as IV infusion

    Also known as: Yervoy

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in experimental arm relative to comparator arm

    OS is defined as the time from randomization until the date of death due to any cause.

    Time frame: up to approximately 61 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization until the date of death due to any cause.

    Time frame: up to approximately 61 months

  2. Progression Free Survival (PFS)

    PFS is defined as the time from randomization until progression per mRECIST 1.1 and/or RECIST 1.1 as assessed by the investigator at local site, or death due to any cause.

    Time frame: up to approximately 61 months

  3. Landmark OS

    Landmarks of OS12, OS18, OS24, and OS36.

    Time frame: 12, 18, 24, 36 months

  4. Landmark PFS

    Landmarks of PFS6, PFS12, PFS18, and PFS24

    Time frame: 6, 12, 18, 24 months

  5. Overall Response Rate (ORR)

    Proportion of participants who have a confirmed Complete Response or confirmed Partial Response, as determined by the investigator at local site per mRECIST 1.1 and/or RECIST 1.1.

    Time frame: up to approximately 61 months

  6. Duration of Response (DoR)

    DoR defined as the time from the date of first documented response until date of documented progression per mRECIST 1.1 and/or RECIST 1.1 as assessed by the investigator at local site or death due to any cause.

    Time frame: up to approximately 61 months

  7. PFS2

    PFS2 defined as the time from randomization to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death.

    Time frame: up to approximately 61 months

  8. Patient-reported physical functioning

    TTD in physical functioning as measured by PROMIS (Patient Reported Outcomes Measurement Information System) Physical Function Short Form 8c. There are 8 questions each from a scale of 1 (unable to do) to a scale of 5 (With a little difficulty). The higher the scores the better the patient-reported physical functioning is.

    Time frame: up to approximately 61 months.

  9. Disease-related symptoms using EORTC IL305 (Q1)

    Change from baseline in disease-related symptoms as measured by individual symptom items from the EORTC (European Organisation For Research And Treatment Of Cancer) IL305 (Item Library 305) (Q1). It is scored from a 1 (not at all) to a 4 (very much). The higher the score the higher the disease-related symptoms.

    Time frame: Up to approximately 61 months.

  10. Disease-related symptoms using PRO-CTCAE (Q1, 5, 6, 9)

    Change from baseline in disease-related symptoms as measured by individual symptom items from the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) (Q1, 5, 6, 9). PRO-CTCAE responses are scored from 0 to 4 (or 0/1 for absent/present). The higher the score the higher the disease-related symptoms.

    Time frame: Up to approximately 61 months

  11. Patient-reported role functioning using EORTC QLQ-C30 RF subscale (IL305 Q2 3)

    Change from baseline in functioning will be assessed by the following measure: Role functioning: EORTC (European Organisation For Research And Treatment Of Cancer) QLQ (Quality of Life Questionnaire) -C30 RF (Role Functioning) subscale (IL305 Q2 3) (Item Library 305). The questions are from a scale of 1 (not at all) to 4 (very much). The lower the score the higher the patient-reported role functioning is.

    Time frame: up to approximately 61 months

  12. Patient-reported HRQoL (Health-related Quality of Life) using EORTC QLQ-C30 HRQoL subscale (IL305 Q7-8)

    Change from baseline in functioning will be assessed by the following measure: HRQoL: EORTC (European Organisation For Research And Treatment Of Cancer) QLQ (Quality of Life Questionnaire) -C30 HRQoL subscale (IL305 Q7-8) (Item Library 305). The questions are from a scale of 1 (very poor) to 7 (excellent). The higher the score the higher the HRQoL.

    Time frame: Up to approximately 61 months

  13. Immunogenicity of volrustomig

    Incidence of Anti-Drug Antibodies against volrustomig.

    Time frame: up to approximately 61 months

  14. Incidence of Adverse Events (AEs) AEs graded by CTCAE version 5.0

    Incidence of Adverse Events (AEs) AEs graded by CTCAE (Common Terminology Criteria for Adverse Events) version 5.0. Grade refers to the severity of the AE. The CTCAE displays grade 1 (mild) through 5 (death related to AE). Grade 2 (moderate), Grade 3 (Severe) and Grade 4 (Life-threatening consequences).

    Time frame: Up to approximately 61 months

  15. Area under the curve (AUC)

    The concentration of MEDI5752 in serum will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: Up to approximately 61 months

  16. Maximum plasma concentration of the drug (Cmax)

    The concentration of MEDI5752 in serum will be determined (Cmax will be derived).

    Time frame: Up to approximately 61 months

  17. The time taken to reach the maximum concentration (Tmax)

    The concentration of MEDI5752 in serum will be determined (Tmax will be derived).

    Time frame: Up to approximately 61 months

07

Study locations

151 sites
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Portland, Oregon 97225, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Chermside, 4032, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Antwerp, 2020, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 22281-100, Brazil
  • Research Site
    Santo André, 09060-650, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G 1X6, Canada
  • Research Site
    Montreal, Quebec H2X 0C1, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100210, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610042, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Ningbo, 315100, China
  • Research Site
    Qingdao, 266003, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110044, China
  • Research Site
    Taiyuan, 030000, China
  • Research Site
    Taiyuan, 030032, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Aarhus N, 8200, Denmark
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Brest, 29200, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    Le Mans, 72037, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Marseille, 13015, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Paris, 75877, France
  • Research Site
    Rouen, 76031, France
  • Research Site
    Saint-Herblain, 44800, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Berlin, 14109, Germany
  • Research Site
    Bochum, 44791, Germany
  • Research Site
    Cologne, 51109, Germany
  • Research Site
    Essen, 45122, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Georgsmarienhütte, 49124, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Hamburg, 21075, Germany
  • Research Site
    Heidelberg, 69126, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Münster, 48153, Germany
  • Research Site
    Regensburg, 93049, Germany
  • Research Site
    Alessandria, 15100, Italy
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Bergamo, 24125, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Monza, 20052, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Parma, 43100, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Varese, 21100, Italy
  • Research Site
    Amagasaki-shi, 660-8550, Japan
  • Research Site
    Hakodate-shi, 040-8611, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Kitakyushu-shi, 807-8555, Japan
  • Research Site
    Matsuyama, 791-0280, Japan

Showing the first 100 of 151 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Nov 2028, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 24, 2023
StartActual
Nov 9, 2023
Primary completionEst.
Nov 16, 2028
CompletionEst.
Nov 16, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06097728
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Nov 9, 2023
Primary completion
Nov 16, 2028 (estimated)
Completion
Nov 16, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Marjorie G Zauderer, MD
principal investigator · Memorial Slone Kettering (MSK) Cancer Centre
Arnaud Scherpereel, MD
principal investigator · Lille University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Volrustomig

Start the discussion